UMIN-CTR Clinical Trial

Unique ID issued by UMIN C000000215
Receipt number R000000252
Scientific Title Study on Therapeutic Effects of Antiplatelet Drugs in Prevention of Occurrence and Inhibition of Progression of Diabetic Atherosclerosis
Date of disclosure of the study information 2005/10/01
Last modified on 2010/06/23 16:30:53

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study on Therapeutic Effects of Antiplatelet Drugs in Prevention of Occurrence and Inhibition of Progression of Diabetic Atherosclerosis

Acronym

Study of Diabetic Atherosclerosis Prevention by Cilostazol
(DAPC Study)

Scientific Title

Study on Therapeutic Effects of Antiplatelet Drugs in Prevention of Occurrence and Inhibition of Progression of Diabetic Atherosclerosis

Scientific Title:Acronym

Study of Diabetic Atherosclerosis Prevention by Cilostazol
(DAPC Study)

Region

Japan Asia(except Japan)


Condition

Condition

Diabetes

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study is conducted as a large-scale interventional study performed in Asian countries, including Japan and South Korea, to clarify the efficacy and usefulness of antiplatelet drugs in the primary prevention and secondary treatment of diabetic atherosclerosis by chronologically observing the intima-media thickness (IMT) of the carotid artery, which is used as a quantitative index of atherosclerosis and by analyzing the occurrence and progression of large-vessel complications in type 2 diabetic patients with mild atherosclerosis for the purpose of investigating the efficacy of antiplatelet drugs (aspirin and cilostazol) clinically used in a wide range at present.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Change of maximum and mean intima-media thickness (IMT) in bilateral common carotid artery.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Aspirin group (81-100mg/day)
2 years

Interventions/Control_2

Cilostazol group (100-200,g/day)
2 years

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

Patients with type 2 diabetes who are suspected of having arteriosclerosis obliterans (ASO)

Key exclusion criteria

1 Patients with type 1 diabetes or secondary diabetes
2 Patients aged under 40 years old, or over 76 years old
3 Patients with severe ASO rated as Fontaine IIb or over
4 Patients with cerebrovascular disorders rated as Grade 4 or over in Modified Rankin Scale (Severe disorder which needs assistance for personal care and walk)
5 Patients with a medical history of angina or myocardial infarction
6 Patients with severe hepatic dysfunction (liver cirrhosis) or renal dysfunction
(serum creatinine 1.5mg/dl)
7 Patients with congestive heart failure
8 Patients with bleeding tendency or bleeding
9 Patients with severe hematological abnormality
10 Patients with definite homologousfamilial hypercholesterolemia
11 Patients who have allergies or a medical history of hypersensitivity to the investigational drugs
12 Pregnant or lactating women, or women who wish to become pregnant
13 Others whom the investigator judges inappropriate as subjects for this study

Target sample size

400


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yoshimitsu Yamasaki

Organization

Osaka University Graduate School of Medicine

Division name

Department of Internal Medicine and Therapeutics

Zip code


Address

2-2, Yamadaoka Suita-city Osaka, Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Munehide Matsuhisa

Organization

Osaka University Graduate School of Medicine

Division name

Department of Internal Medicine and Therapeutics

Zip code


Address

2-2, Yamadaoka Suita-city Osaka, Japan

TEL


Homepage URL


Email



Sponsor or person

Institute

DAPC Study Steering Committee

Institute

Department

Personal name



Funding Source

Organization

Japan Cardiovascular Research Foundation

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2005 Year 10 Month 01 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2004 Year 08 Month 17 Day

Date of IRB


Anticipated trial start date

2004 Year 12 Month 01 Day

Last follow-up date

2008 Year 06 Month 01 Day

Date of closure to data entry

2008 Year 09 Month 01 Day

Date trial data considered complete

2008 Year 12 Month 01 Day

Date analysis concluded

2009 Year 02 Month 01 Day


Other

Other related information



Management information

Registered date

2005 Year 09 Month 13 Day

Last modified on

2010 Year 06 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000252


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name